Commentary

Kumar, Aman; Agarwal, Divya; Kumar, Atul

doi:10.4103/ijo.ijo_39_21

Cited by 6 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inflammation was hypothesized to occur secondary to the immunogenicity against the molecule. [ 9 , 10 ] However, the incidence reported by the authors in the current study is <0.01%. [ 8 ] Similarly, other authors have also reported that they are increasingly becoming satisfied with the safety profile of razumab.…”

contrasting

confidence: 61%

Commentary: Biosimilars in the treatment of retinopathy of prematurity

Soni

Kohli

2023

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

contrasting

confidence: 61%

Commentary: Biosimilars in the treatment of retinopathy of prematurity

Soni

Kohli

2023

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

“…Intravitreal injection of anti-VEGF compounds is the standard of care treatment of DME. Pivotal studies have demonstrated the efficacy and safety of several biologic anti VEGF compounds among them aflibercept [ 7 ], ranibizumab [ 94 ], and faricimab [ 95 ], as well as more recently biosimilar compounds such as Formycon and Bioeq’s FYB201, MYL-1701, Razumab, ranibizumab-nuna, and ranibizumab-eqrn [ 96 , 97 , 98 ]. Interestingly, many studies have demonstrated that anti-VEGF compounds were not only anti-angiogenic, but also possess anti-inflammatory properties which may contribute in part in their success in the management of retinal pathologies [ 99 , 100 , 101 ].…”

Section: Anti-inflammatory Compounds For the Treatment Of Dme And Amdmentioning

confidence: 99%

Suppressing Inflammation for the Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration: Dazdotuftide as a Potential New Multitarget Therapeutic Candidate

Vofo

Chowers

2023

Biomedicines

View full text Add to dashboard Cite

Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are major causes of blindness globally. The primary treatment option for DME and neovascular AMD (nAMD) is anti-vascular endothelial growth factor (VEGF) compounds, but this treatment modality often yields insufficient results, and monthly injections can place a burden on the health system and patients. Although various inflammatory pathways and mediators have been recognized as key players in the development of DR and AMD, there are limited treatment options targeting these pathways. Molecular pathways that are interlinked, or triggers of multiple inflammatory pathways, could be promising targets for drug development. This review focuses on the role of inflammation in the pathogenesis of DME and AMD and presents current anti-inflammatory compounds, as well as a potential multitarget anti-inflammatory compound (dazdotuftide) that could be a candidate treatment option for the management of DME and AMD.

show abstract

“…Financial constraint plays a big role in selection of one agent, and to reduce the financial burden of FDA-approved anti-VEGF, biosimilars like razumab are commonly used but there are still concerns regarding their safety. [ 3 ] Similarly, ultrawide field Fluorescein angiography (FA) has its own niche in retinal diseases affecting the periphery such as diabetes mellitus and retinal vascular occlusion. [ 4 ] It is one investigation worth investing in for the longer run.…”

mentioning

confidence: 99%